Late BCNU lung: A light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma

P. S. Hasleton, B. R. O'Driscoll, Peter J Lynch, A. Webster, S. J. Kalra, H. R. Gattamaneini, A. A. Woodcock, L. W. Poulter

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We describe eight patients who developed interstitial pulmonary fibrosis following BCNU (carmustine) therapy for cerebral tumours. The fibrosis presented 12–17 (mean 14) years after exposure to the drug. A distinctive pattern of pulmonary fibrosis with involvement of the apices and subpleural areas was seen in one patient dying of the disease. Light microscopy showed interstitial elastosis and intra‐alveolar fibrosis which was often focal with an associated mild lymphoplasmacytic infiltrate, intra‐alveolar oedema, macrophages, and some neutrophils. Ultrastructural studies showed electron lucency of type I pneumocytes, with breaks in the cytoplasmic membranes leaving a bare basement membrane. Degenerative change was also seen in endothelial cell cytoplasm along with lipofuscin deposition. While BCNU pulmonary fibrosis has been described up to 2 years after treatment, this complication so late after therapy, though rare, has important implications for the follow‐up of patients receiving this drug.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalThe Journal of Pathology
Volume164
Issue number1
DOIs
StatePublished - Jan 1 1991

Fingerprint

Carmustine
Pulmonary Fibrosis
Light
Lung
Fibrosis
Alveolar Epithelial Cells
Lipofuscin
Basement Membrane
Pharmaceutical Preparations
Microscopy
Edema
Cytoplasm
Neutrophils
Therapeutics
Endothelial Cells
Macrophages
Cell Membrane
Electrons
Neoplasms

Keywords

  • BCNU
  • Interstitial pulmonary fibrosis

Cite this

Hasleton, P. S., O'Driscoll, B. R., Lynch, P. J., Webster, A., Kalra, S. J., Gattamaneini, H. R., ... Poulter, L. W. (1991). Late BCNU lung: A light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma. The Journal of Pathology, 164(1), 31-36. https://doi.org/10.1002/path.1711640106

Late BCNU lung : A light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma. / Hasleton, P. S.; O'Driscoll, B. R.; Lynch, Peter J; Webster, A.; Kalra, S. J.; Gattamaneini, H. R.; Woodcock, A. A.; Poulter, L. W.

In: The Journal of Pathology, Vol. 164, No. 1, 01.01.1991, p. 31-36.

Research output: Contribution to journalArticle

Hasleton, PS, O'Driscoll, BR, Lynch, PJ, Webster, A, Kalra, SJ, Gattamaneini, HR, Woodcock, AA & Poulter, LW 1991, 'Late BCNU lung: A light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma', The Journal of Pathology, vol. 164, no. 1, pp. 31-36. https://doi.org/10.1002/path.1711640106
Hasleton PS, O'Driscoll BR, Lynch PJ, Webster A, Kalra SJ, Gattamaneini HR et al. Late BCNU lung: A light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma. The Journal of Pathology. 1991 Jan 1;164(1):31-36. https://doi.org/10.1002/path.1711640106
Hasleton, P. S. ; O'Driscoll, B. R. ; Lynch, Peter J ; Webster, A. ; Kalra, S. J. ; Gattamaneini, H. R. ; Woodcock, A. A. ; Poulter, L. W. / Late BCNU lung : A light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma. In: The Journal of Pathology. 1991 ; Vol. 164, No. 1. pp. 31-36.
@article{2e9489754c1c483eae0d0ae338885df4,
title = "Late BCNU lung: A light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma",
abstract = "We describe eight patients who developed interstitial pulmonary fibrosis following BCNU (carmustine) therapy for cerebral tumours. The fibrosis presented 12–17 (mean 14) years after exposure to the drug. A distinctive pattern of pulmonary fibrosis with involvement of the apices and subpleural areas was seen in one patient dying of the disease. Light microscopy showed interstitial elastosis and intra‐alveolar fibrosis which was often focal with an associated mild lymphoplasmacytic infiltrate, intra‐alveolar oedema, macrophages, and some neutrophils. Ultrastructural studies showed electron lucency of type I pneumocytes, with breaks in the cytoplasmic membranes leaving a bare basement membrane. Degenerative change was also seen in endothelial cell cytoplasm along with lipofuscin deposition. While BCNU pulmonary fibrosis has been described up to 2 years after treatment, this complication so late after therapy, though rare, has important implications for the follow‐up of patients receiving this drug.",
keywords = "BCNU, Interstitial pulmonary fibrosis",
author = "Hasleton, {P. S.} and O'Driscoll, {B. R.} and Lynch, {Peter J} and A. Webster and Kalra, {S. J.} and Gattamaneini, {H. R.} and Woodcock, {A. A.} and Poulter, {L. W.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1002/path.1711640106",
language = "English (US)",
volume = "164",
pages = "31--36",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Late BCNU lung

T2 - A light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma

AU - Hasleton, P. S.

AU - O'Driscoll, B. R.

AU - Lynch, Peter J

AU - Webster, A.

AU - Kalra, S. J.

AU - Gattamaneini, H. R.

AU - Woodcock, A. A.

AU - Poulter, L. W.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - We describe eight patients who developed interstitial pulmonary fibrosis following BCNU (carmustine) therapy for cerebral tumours. The fibrosis presented 12–17 (mean 14) years after exposure to the drug. A distinctive pattern of pulmonary fibrosis with involvement of the apices and subpleural areas was seen in one patient dying of the disease. Light microscopy showed interstitial elastosis and intra‐alveolar fibrosis which was often focal with an associated mild lymphoplasmacytic infiltrate, intra‐alveolar oedema, macrophages, and some neutrophils. Ultrastructural studies showed electron lucency of type I pneumocytes, with breaks in the cytoplasmic membranes leaving a bare basement membrane. Degenerative change was also seen in endothelial cell cytoplasm along with lipofuscin deposition. While BCNU pulmonary fibrosis has been described up to 2 years after treatment, this complication so late after therapy, though rare, has important implications for the follow‐up of patients receiving this drug.

AB - We describe eight patients who developed interstitial pulmonary fibrosis following BCNU (carmustine) therapy for cerebral tumours. The fibrosis presented 12–17 (mean 14) years after exposure to the drug. A distinctive pattern of pulmonary fibrosis with involvement of the apices and subpleural areas was seen in one patient dying of the disease. Light microscopy showed interstitial elastosis and intra‐alveolar fibrosis which was often focal with an associated mild lymphoplasmacytic infiltrate, intra‐alveolar oedema, macrophages, and some neutrophils. Ultrastructural studies showed electron lucency of type I pneumocytes, with breaks in the cytoplasmic membranes leaving a bare basement membrane. Degenerative change was also seen in endothelial cell cytoplasm along with lipofuscin deposition. While BCNU pulmonary fibrosis has been described up to 2 years after treatment, this complication so late after therapy, though rare, has important implications for the follow‐up of patients receiving this drug.

KW - BCNU

KW - Interstitial pulmonary fibrosis

UR - http://www.scopus.com/inward/record.url?scp=0025758390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025758390&partnerID=8YFLogxK

U2 - 10.1002/path.1711640106

DO - 10.1002/path.1711640106

M3 - Article

C2 - 2056387

AN - SCOPUS:0025758390

VL - 164

SP - 31

EP - 36

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 1

ER -